EA201171439A1 - Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида - Google Patents

Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида

Info

Publication number
EA201171439A1
EA201171439A1 EA201171439A EA201171439A EA201171439A1 EA 201171439 A1 EA201171439 A1 EA 201171439A1 EA 201171439 A EA201171439 A EA 201171439A EA 201171439 A EA201171439 A EA 201171439A EA 201171439 A1 EA201171439 A1 EA 201171439A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
sulphonamido
amyloid peptide
beta amyloid
peptide product
Prior art date
Application number
EA201171439A
Other languages
English (en)
Inventor
мл. Джон Е. Стэрретт
Кевин В. Джиллман
Ричард Е. Олсон
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171439(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201171439A1 publication Critical patent/EA201171439A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В настоящем изобретении предлагается новое соединение алфа-(N-сульфонамидо)ацетамид, его фармацевтический состав, технологические процессы и способ лечения болезни Альцгеймера и других состояний, ассоциированных с β-амилоидным пептидом.
EA201171439A 2007-10-31 2008-10-14 Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида EA201171439A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
EA201171439A1 true EA201171439A1 (ru) 2012-05-30

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000714A EA016447B1 (ru) 2007-10-31 2008-10-14 Соединение альфа-(n-сульфонамидо) ацетамида в качестве ингибитора продуцирования бета амилоидного пептида
EA201171439A EA201171439A1 (ru) 2007-10-31 2008-10-14 Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201000714A EA016447B1 (ru) 2007-10-31 2008-10-14 Соединение альфа-(n-сульфонамидо) ацетамида в качестве ингибитора продуцирования бета амилоидного пептида

Country Status (29)

Country Link
US (2) US8084477B2 (ru)
EP (3) EP2471769A1 (ru)
JP (1) JP5460605B2 (ru)
KR (1) KR20100075575A (ru)
CN (2) CN101910141B (ru)
AR (1) AR069135A1 (ru)
AT (1) ATE502022T1 (ru)
AU (1) AU2008319122A1 (ru)
BR (1) BRPI0818837A2 (ru)
CA (1) CA2704360A1 (ru)
CL (1) CL2008003271A1 (ru)
CO (1) CO6270332A2 (ru)
CY (2) CY1112337T1 (ru)
DE (1) DE602008005636D1 (ru)
DK (2) DK2295417T3 (ru)
EA (2) EA016447B1 (ru)
ES (2) ES2361283T3 (ru)
HK (2) HK1141801A1 (ru)
HR (2) HRP20110219T1 (ru)
IL (1) IL205406A0 (ru)
MX (1) MX2010004319A (ru)
NZ (1) NZ584545A (ru)
PE (1) PE20091394A1 (ru)
PL (2) PL2205575T3 (ru)
PT (2) PT2295417E (ru)
SG (2) SG174044A1 (ru)
SI (2) SI2205575T1 (ru)
TW (1) TW200927099A (ru)
WO (1) WO2009058552A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2408450B1 (en) * 2009-03-19 2013-03-13 Bristol-Myers Squibb Company Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
BR122017023130B1 (pt) 2010-03-12 2018-03-06 Nippon Soda Co., Ltd. Derivado de tetrazoliloxima, métodos de produção de derivados de tetrazoliloxima
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012069428A1 (en) * 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047390A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
IL267253B2 (en) 2016-12-16 2023-04-01 Pipeline Therapeutics Inc Methods for treating cochlear synaptopathy
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
US20220332821A1 (en) 2019-06-24 2022-10-20 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE69624262T2 (de) 1995-11-17 2003-09-11 Warner Lambert Co Sulfonamidinhibitoren von matrix metalloproteinasen
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1224612C (zh) 1999-01-27 2005-10-26 惠氏控股有限公司 炔基磺酰胺硫醇tace抑制剂
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
IL159140A0 (en) * 2001-12-14 2004-06-01 Raytheon Co Precisely aligned lens structure and a method for its fabrication
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
PL372090A1 (en) * 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
EP1460070B1 (en) * 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
CN1780829B (zh) 2003-03-31 2010-12-29 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
TW200736195A (en) 2006-02-17 2007-10-01 Wyeth Corp Methods for preparing sulfonamide substituted alcohols and intermediates thereof
BRPI0707742A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
PE20091394A1 (es) 2009-09-25
JP5460605B2 (ja) 2014-04-02
EP2205575B1 (en) 2011-03-16
EP2471769A1 (en) 2012-07-04
CN102718689A (zh) 2012-10-10
TW200927099A (en) 2009-07-01
US20120088925A1 (en) 2012-04-12
ES2361283T3 (es) 2011-06-15
PT2205575E (pt) 2011-05-23
ATE502022T1 (de) 2011-04-15
EA201000714A1 (ru) 2010-10-29
PL2295417T3 (pl) 2012-11-30
HRP20110219T1 (hr) 2011-04-30
HRP20120703T1 (hr) 2012-09-30
DK2205575T3 (da) 2011-07-11
IL205406A0 (en) 2010-12-30
NZ584545A (en) 2011-04-29
CN101910141A (zh) 2010-12-08
PL2205575T3 (pl) 2011-09-30
US20090111858A1 (en) 2009-04-30
PT2295417E (pt) 2012-09-26
SI2205575T1 (sl) 2011-07-29
BRPI0818837A2 (pt) 2015-04-22
EP2205575A1 (en) 2010-07-14
DE602008005636D1 (de) 2011-04-28
US8084477B2 (en) 2011-12-27
HK1155161A1 (en) 2012-05-11
WO2009058552A1 (en) 2009-05-07
EP2295417B1 (en) 2012-07-04
CY1112337T1 (el) 2015-12-09
SI2295417T1 (sl) 2012-11-30
US8350084B2 (en) 2013-01-08
SG174043A1 (en) 2011-09-29
SG174044A1 (en) 2011-09-29
HK1141801A1 (en) 2010-11-19
EP2295417A1 (en) 2011-03-16
AR069135A1 (es) 2009-12-30
CA2704360A1 (en) 2009-05-07
CL2008003271A1 (es) 2009-07-10
EA016447B1 (ru) 2012-05-30
CO6270332A2 (es) 2011-04-20
JP2011502153A (ja) 2011-01-20
ES2390042T3 (es) 2012-11-06
CY1113346T1 (el) 2016-06-22
DK2295417T3 (da) 2012-10-15
AU2008319122A1 (en) 2009-05-07
CN101910141B (zh) 2012-12-19
MX2010004319A (es) 2010-04-30
KR20100075575A (ko) 2010-07-02

Similar Documents

Publication Publication Date Title
EA201171439A1 (ru) Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
CL2004001011A1 (es) Compuestos azabiciclicos derivados de n-arilsulfonilpiperidinas; inhibidores de la deposicion de la proteina beta amiloide; composicion farmaceutica; y su uso para el tratamiento del alzheimer y enfermedades neurodegenerativas.
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
DK1847524T3 (da) Terphenylderivater til behandling af Alzheimers sygdom
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
WO2008104385A8 (en) Method for the treatment of amyloidoses
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit